Precision BioLogic Gains Traction in Hemostasis Testing Market

The Halifax-based company saw heightened engagement at the ISTH 2026 conference in Paris, where clinicians sought clarity on measuring factor levels against emerging bispecific antibodies. CEO Paul Empey noted that the firm’s bovine Chromogenic Factor VIII assay is becoming a critical resource for labs navigating the transition from traditional replacement products to newer mimetics. Beyond its diagnostic offerings, the company presented research on lupus anticoagulant assays and modified testing methods for inhibitor titers, further cementing its role in coagulation research.

Following the Paris event, the organization maintained its momentum with a tour of major medical forums, including the ADLM 2026 meeting in Anaheim and the NBDF Bleeding Disorders Conference in Orlando. These engagements highlighted the integration of the company’s three branches: Precision BioLogic’s diagnostic reach, Affinity Biologicals’ manufacturing capabilities, and George King Bio-Medical’s deep ties to patient communities. By aligning specialized manufacturing with direct clinical support, the group is scaling its influence across the global hemostasis sector.